The Association of Alpha-Blockers and 5-Alpha Reductase Inhibitors in Benign Prostatic Hyperplasia With Fractures

2014 ◽  
Vol 347 (6) ◽  
pp. 463-471 ◽  
Author(s):  
Sian Yik Lim ◽  
Pavis Laengvejkal ◽  
Ragesh Panikkath ◽  
Kenneth Nugent
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Alpha Blockers ◽  
Reductase Inhibitors ◽  
5 Alpha Reductase Inhibitors

Evaluation of Recent Trends in Treatment Patterns Among Men With Benign Prostatic Hyperplasia

2012 ◽  
Vol 7 (3) ◽  
pp. 214-219 ◽  
Author(s):  
Eric J. Kruep ◽  
Bridgett B. Goodwin ◽  
Sham Chaudhari
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Real World ◽  
Prostatic Hyperplasia ◽  
Alpha Blockers ◽  
Reductase Inhibitors ◽  
Real World Evidence ◽  
Final Sample ◽  
Risk Of Disease ◽  
Recent Trends ◽  
5 Alpha Reductase Inhibitors

Although there is an abundance of evidence regarding clinical efficacy and safety of benign prostatic hyperplasia (BPH) treatment, real-world evidence is lacking for pharmacotherapy utilization and trends. It is unclear how evidence demonstrating the efficacy of combination 5-alpha reductase inhibitors and alpha blockers for improving symptoms and reducing risk of disease progression translates into real-world practice for the treatment of BPH. A retrospective study of a database was conducted to describe pharmacotherapy utilization/trends in the treatment of BPH among patients in the managed care setting. After inclusion and exclusion criteria were applied, the final sample size was 107,038. The proportion of patients with BPH receiving 5-alpha reductase inhibitors therapy increased (21.1% in 2003 to 30.5% in 2007), as did the proportion receiving combination therapy (10.7% and 16.1%, respectively). We observed an almost 50% increase in 5-alpha reductase inhibitors use over 5 years and a 60% increase in the use of combination 5-alpha reductase inhibitors/alpha blockers therapy.

scholarly journals Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors

Uro ◽  
2021 ◽  
Vol 1 (3) ◽  
pp. 82-98
Author(s):  
Antonio La Torre ◽  
Caterina Palleria ◽  
Irene Tamanini ◽  
Andrea Scardigli ◽  
Tommaso Cai ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Sexual Dysfunction ◽  
Lower Urinary Tract ◽  
Prostatic Hyperplasia ◽  
Sexual Dysfunctions ◽  
Reductase Inhibitors ◽  
Urinary Tract Symptoms ◽  
5 Alpha Reductase Inhibitors ◽  
Lower Urinary

This is a critical review of the current literature data about sexual dysfunction as a potential side effect related to drugs commonly used for the treatment of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms. In this narrative review, we analyzed data from the literature related to the development of sexual dysfunctions during the treatment of BPH or LUTS. Both α-blockers and 5-alpha reductase inhibitors (5-ARIs) can induce erectile dysfunction, ejaculatory disorders and a reduction in sexual desire. The sexual side effect profile of these drugs is different. Among the α-blockers, silodosin appears to have the highest incidence of ejaculatory disorders. Persistent sexual side effects after the discontinuation of finasteride have been recently reported; however, further studies are needed to clarify the true incidence and the significance of this finding. However, most of the published studies are affected by a weak methodology and other important limitations, with only a few RCTs available. Therefore, it is desirable that future studies will include validated tools to assess and diagnose the sexual dysfunction induced by these medications, especially for ejaculation and sexual desire disorders.

5‐alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia

2021 ◽  
Author(s):  
Diya B. Joseph ◽  
Gervaise H. Henry ◽  
Alicia Malewska ◽  
Jeffrey C. Reese ◽  
Ryan J. Mauck ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Club Cell ◽  
Reductase Inhibitors ◽  
5 Alpha Reductase Inhibitors ◽  
Cell Transition

Impact of Preoperative Therapy with 5-α-Reductase Inhibitors in the Treatment of Benign Prostatic Hyperplasia

2012 ◽  
Vol 79 (2) ◽  
pp. 149-151
Author(s):  
Giacomo De Stefano ◽  
Ferdinando Fusco ◽  
Davide Arcaniolo ◽  
Antonio Pistone ◽  
Marco Capece ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prospective Observational Study ◽  
Progressive Disease ◽  
Prostatic Hyperplasia ◽  
Preoperative Therapy ◽  
Reductase Inhibitors ◽  
Favorable Influence ◽  
The Impact ◽  
5 Alpha Reductase Inhibitors

Benign prostatic hyperplasia is considered a progressive disease intimately linked with aging. The long-term use of combination therapy with a 5-alpha-reductase inhibitor, together with an alpha blocker in men with moderate-severe symptoms, reduces the risk of clinical progression and BPH-related surgery. It is unclear what the impact is of preoperative therapy with 5-ARI in patients that undergo surgery. The aim of our study was to evaluate the impact of preoperative therapy with 5-alpha-reductase inhibitors on: a) indication on the type of surgery; b) surgical and functional outcomes; c) surgical complications. This is a prospective observational study. It will include all patients undergoing surgery by TURP or Open Prostatectomy in a period of 24 months. We expect results that demonstrate significant and favorable influence of pretreatment with 5-alpha-reductase inhibitors on certain outcomes. Therefore, therapy with 5-ARI could be considered as neoadjuvant to surgery, whatever this is.

Sign in / Sign up

Export Citation Format

Share Document